Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target Lowered to $41.00 at Piper Sandler
Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) had its price objective lowered by Piper Sandler from $45.00 to $41.00 in a research note released on Wednesday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the specialty pharmaceutical company’s stock. Separately, StockNews.com upgraded shares of Supernus Pharmaceuticals from a hold rating to a buy […]
More Stories
Office Romance is Released! Watch Jennifer Lopez and Brett Goldstein’s Exotic Romance
Looking for a romantic-comedy film to watch with your partner or loved ones this weekend? Jennifer Lopez’s recent film, Office...
The Quiet Logistics Shift Changing How Shoppers Collect Fresh Food
Nobody talks about this, but it’s happening everywhere. The way grocery stores handle order collection is changing. Not in a...
Why Offices Sound Worse Than Ever, And the Engineering Fix Hiding in Plain Sight
Open-plan offices were meant to feel modern, bright, and collaborative. In reality, many feel like a mix of café, hallway,...
Ice Age 6: Boiling Point- Release Date, Voice Artist, and Synopsis
Hello, Ice Age fans! Your favourite animated animal movie is returning to the US theaters. Ice Age 6, or Ice...
I Will Find You: Sam Worthington’s Upcoming Series
Netflix is coming up with an all-new miniseries featuring the famous Sam Worthington as Jake Sully from the 2009 film...
Big Mistakes Season 2: Release Date, Cast, and Synopsis
Netflix’s hit comedy-thriller series, Big Mistakes, got an official renewal. The dark comedy series is bringing back the humor of...